XTX Topco Ltd Grows Position in 2seventy bio, Inc. (NASDAQ:TSVT)

XTX Topco Ltd raised its position in 2seventy bio, Inc. (NASDAQ:TSVT) by 61.1% during the third quarter, HoldingsChannel.com reports. The firm owned 24,416 shares of the company’s stock after purchasing an additional 9,257 shares during the period. XTX Topco Ltd’s holdings in 2seventy bio were worth $115,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Erste Asset Management GmbH purchased a new stake in shares of 2seventy bio in the third quarter worth approximately $25,000. Readystate Asset Management LP bought a new position in 2seventy bio in the 3rd quarter valued at $53,000. SkyView Investment Advisors LLC increased its stake in 2seventy bio by 25.0% in the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after purchasing an additional 2,500 shares during the period. GSA Capital Partners LLP bought a new stake in shares of 2seventy bio during the third quarter worth $64,000. Finally, Nisa Investment Advisors LLC bought a new stake in shares of 2seventy bio during the second quarter worth $52,000. Institutional investors own 93.90% of the company’s stock.

2seventy bio Trading Up 7.5 %

NASDAQ TSVT opened at $3.14 on Friday. The stock has a market cap of $161.99 million, a PE ratio of -1.69 and a beta of 1.69. 2seventy bio, Inc. has a 12 month low of $2.78 and a 12 month high of $6.40. The company’s 50-day moving average price is $4.11 and its 200-day moving average price is $4.31.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.